Skip to main content
. 2017 Feb 17;8(11):18312–18321. doi: 10.18632/oncotarget.15436

Figure 3. AMPKα1 mutation inhibits NPC-26-induced killing of HCT-116 cells.

Figure 3

Puromycin-selected HCT-116 cells, expressing dominant negative AMPKα1 (“dn-AMPKα1”, T172D) or empty vector, were treated with/out NPC-26 (10 μM) for applied time, listed proteins were shown A.; Cell death B. were tested. HT-29 cells or FHC colon epithelial cells were treated with designated concentration of NPC-26 for 4 hours, expression of listed proteins was shown C. and D. For each assay, n=5. Experiments in this figure were repeated three times, and similar results were obtained each time. AMPKα1/ACC phosphorylation (vs. total protein, or vs. tubulin when mentioned) was quantified (A). * p <0.05 vs. “C”. # p <0.05 vs. “Vector”.